NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more

Pipeline updates for BIND CTIC DERM + ALKS to initiate pivotal ALKS 3831 trial

Jan 08, 2015 No Comments

Latest updates to the Company Pipeline Database from January 7, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALKS 66.75 ALKS 3831 Schizophrenia Phase 2 Phase 2 data released Jan 2015.Met primary endpoint, equivalence to olanzapine. Pivotal trial planned for 2015 1/8/2015 BIND 5.15 BIND-014 Cancer – […]

Read more

KBIO Phase 2 trial failure. CNAT data due this week + updates for ARIA CANF RARE TNXP TRVN AKBA BCLI CEMP CYTR MSTX RVNC RLYP GEVA

Jan 07, 2015 No Comments

Latest updates to the Company Pipeline Database from January 5 and 6, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ARIA 6.51 Iclusig (ponatinib) Cancer – refractory chronic-phase chronic myeloid leukemia (CP-CML) Phase 2 Phase 2 dose ranging trial to be initiated mid 2015 1/7/2015 CANF […]

Read more

Happy New Year + updates from AQXP CANF RPRX SYN TKMR XENT

Jan 01, 2015 No Comments

A very special Happy New Year to all readers of BioPharmCatalyst! Thank you for your support over the past year and I wish you a most prosperous 2015. Latest updates to the Company Pipeline Database from December 30 and 31,2014. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated […]

Read more

ATHX Multistem data due around end 1Q 2015. PTN initiates Phase 3 FSD trial.

Dec 29, 2014 No Comments

Latest updates to the Company Pipeline Database from December 26,2014. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ATHX 1.41 Multistem Ischemic stroke Phase 2 Initiated 3Q 2011. Enrolment completed late Dec 2014. Initial data due around the end of 1Q 2015 12/30/2014 PTN 0.79 Bremelanotide female […]

Read more

SPPI LGND file NDA for Captisol-Enabled Melphalan

Dec 27, 2014 No Comments

Latest updates to the Company Pipeline Database from December 26,2014. Refer to the FDA Calendar for upcoming catalysts: I hope everyone has had a chance to rest up and put up their feet over the Christmas break with friends and family. There is just one update today, from SPPI regarding their NDA filing for Captisol-Enabled Melphalan. Ticker Price Drug […]

Read more

BDSI ENDP file NDA + updates for CMRX PTCT

Dec 24, 2014 No Comments

Latest updates to the Company Pipeline Database from December 22,2014. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Info Updated BDSI 11.99 BEMA Buprenorphine Opioid experienced patient group NDA Announced Dec 23 2014 that they have submitted their NDA filing 12/24/2014 CMRX 36.1 SUPPRESS trial of CMX001 Cytomegalovirus (CMV) infection […]

Read more

BCRX FDA Approval. Data from ACHN RDUS + BCLI SYN ALIOF RCPT CANF PCYC updates

Dec 23, 2014 No Comments

Latest updates to the Company Pipeline Database from December 22,2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ACHN 15.49 ACH-3102 + Sovaldi Treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection Phase 2 100 percent SVR4 results reported late Dec 2014 following six weeks of treatment […]

Read more

CERS receives second PMA Approval. IMGN RHHBY release Phase 3 data + FATE SGYP TLOG updates

Dec 19, 2014 No Comments

Latest updates to the Company Pipeline Database from December 18  2014. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Link Text Updated CERS 6.16 INTERCEPT Platelets Approved PMA approved Dec 18 2014 12/19/2014 FATE 3.7 ProHema Adult hematologic malignancies Phase 2 Phase 2 data due mid-2015. 12/19/2014 IMGN 10.85 Kadcyla […]

Read more